Latest Conference Articles

Amanda Hickman, PharmD, MPH, MSCS, discusses the clinical assessment to lower migraines (CALM) in an HSSP setting.

Individuals with HR+ breast cancer could pause endocrine therapy for up to 2 years to become pregnant, without increasing the risk of recurrence.

Patients with an estrogen receptor measure greater than 8% and those with little to no TIL expression showed no benefit with the addition of nivolumab.

Carly Giavatto, PharmD, discusses the CPS conducted study that highlights a first of its kind linkage to care initiative performed by health systems specialty pharmacists.

The investigational combination also delayed the median time to first chemotherapy in all age groups.

Biologic rationale, biomarker precision, and efficacy results in the biomarker-negative population all helped FDA officials decide the final indication.

Evidence has shown that reversing pro-cancer effects requires significant weight loss as well as substantial metabolic reprogramming.

Patients with breast cancer who underwent chemotherapy and skipped RNI did not face an increased risk of disease recurrence or death 5 years post-surgery.

Although PFS was improved in patients with unresectable locally advanced or metastatic HER2-positive breast cancer, OS data were immature, requiring further research.

Trastuzumab deruxtecan and elacestrant both represent important new treatment options for subgroups of patients with breast cancer.

Peter J. Siavelis, discusses the role of the InteLogix platform to enable a more rapid response to changes in the pharmaceutical supply chain.

Pharmacy Times will be covering the 2023 San Antonio Breast Cancer Symposium (SABCS), happening December 5 through 9 in Texas.

Jennifer N. Clements PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP discusses the role of Semaglutide and Tirzepatide for type 2 diabetes and obesity

Pharmacists address aspects of patient care that are unique to the focus of the pharmacist, such as financial toxicity and data collection for components of social determinants of health (SDOH).

A single infusion of VERVE-101, a gene editing tool, improved both blood PCSK9 protein levels and blood LDL-C levels in 10 individuals with high-risk HeFH.

Session speaker Powell-Wiley explains how screening for SDOH in patients as cardiovascular-kidney-metabolic syndrome stages progress can help better understand their individual social needs.

Ince describes why patients who are considered fragile are often underdiagnosed and undertreated, and that the VOYAGER PAD analyses can encourage the treatment of the fragile population.

The AZALEA-TIMI 71 randomized trial evaluated the safety and tolerability of 2 blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban.

Bonaca also notes that pharmacists can play a key role in educating patients and clinicians about the appropriate use and dosing of antithrombotic drugs for vascular protection.

Harrington discusses how the performance of milvexian in prior phase 2 trials focused on different patient populations creates the foundation for future research.

Sehnert emphasizes that mavacamten treatment benefits were present in both patients with sarcomere mutation positive HCM and sarcomere mutation negative HCM.

Clinically meaningful lowering of blood pressure through reduction in dietary sodium was achieved safely and rapidly in 1 week in a middle-aged and elderly cohort.

Elevated Lp(a), which was previously untreatable, may become treatable in the near future, according to the study investigator.

The SPRINT trial was the first to demonstrate the benefit of further reduction in blood pressure, but it included a limited Asian population and excluded patients with diabetes or history of stroke.

The SELECT trial expands on existing literature that have shown safety and cardiovascular benefit in individuals with diabetes to now also show benefit in obesity.

The American Heart Association published a statement describing the cardiovascular-kidney-metabolic (CKM) construct, specifically highlighting treatment challenges for CKM syndrome.

Experts discuss challenges and recommendations for addressing diversity, equity, and inclusion in pharmacy programs for minority students.

Regular usage of cannabis may increase the risk of heart failure, stroke, or heart attack, even after adjusting for other cardiovascular disease risk factors.